Panbela Therapeutics Inc (PBLA)
0.43
-0.01
(-1.21%)
USD |
OTCM |
Apr 30, 16:00
Panbela Therapeutics Cash from Financing (TTM): 26.14M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 26.14M |
September 30, 2023 | 26.74M |
June 30, 2023 | 26.77M |
March 31, 2023 | 19.06M |
December 31, 2022 | 5.354M |
September 30, 2022 | 0.006M |
June 30, 2022 | 9.054M |
March 31, 2022 | 9.054M |
December 31, 2021 | 10.10M |
September 30, 2021 | 9.384M |
June 30, 2021 | 9.69M |
March 31, 2021 | 11.51M |
December 31, 2020 | 10.44M |
September 30, 2020 | 11.09M |
June 30, 2020 | 4.85M |
March 31, 2020 | 3.00M |
December 31, 2019 | 3.784M |
September 30, 2019 | 5.174M |
June 30, 2019 | 2.032M |
March 31, 2019 | 2.79M |
December 31, 2018 | 3.643M |
September 30, 2018 | 2.314M |
June 30, 2018 | 2.341M |
Date | Value |
---|---|
March 31, 2018 | 1.651M |
December 31, 2017 | 3.106M |
September 30, 2017 | 3.148M |
June 30, 2017 | 3.418M |
March 31, 2017 | 4.981M |
December 31, 2016 | 1.915M |
September 30, 2016 | 1.873M |
June 30, 2016 | 2.766M |
March 31, 2016 | 2.241M |
December 31, 2015 | 2.675M |
September 30, 2015 | 3.079M |
June 30, 2015 | 4.331M |
March 31, 2015 | 3.251M |
December 31, 2014 | 2.815M |
September 30, 2014 | 2.405M |
June 30, 2014 | -0.0115M |
March 31, 2014 | -0.0107M |
December 31, 2013 | -0.0116M |
September 30, 2013 | -0.0103M |
June 30, 2013 | -0.0255M |
March 31, 2013 | -0.0055M |
December 31, 2012 | 0.0069M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.006M
Minimum
Sep 2022
26.77M
Maximum
Jun 2023
10.70M
Average
9.384M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
Processa Pharmaceuticals Inc | 6.269M |
Fate Therapeutics Inc | 0.085M |
Ardelyx Inc | 146.30M |
Checkpoint Therapeutics Inc | 40.45M |
Palisade Bio Inc | 11.19M |